---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Effects on other drugs"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Effects on other drugs. Topics: Sensitive CYP3A4 substrate: midazolam, In vitro CYP3A4 induction and removal of the CYP3A substrate restriction, and Combined oral contraceptives: ethinyl estradiol and levonorgestrel. 3 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/effects-on-other-drugs"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Effects on other drugs

<a id="heading-2.1.2.9.2"></a>

## 2.1.2.9.2 Effects of Inaxaplin on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

### Sensitive CYP3A4 substrate: midazolam

> “We assessed the potential of inaxaplin to either induce or inhibit CYP3A4 enzymes in Study 1 by measuring the effect of inaxaplin administration on serum concentrations of midazolam, a sensitive CYP3A4 substrate.”
> “There were no clinically significant PK drug-drug interactions between inaxaplin and midazolam (online Table S3).”
> “Inaxaplin is not a clinically significant inhibitor or inducer of CYP3A4.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.9.2-2"></a>

### In vitro CYP3A4 induction and removal of the CYP3A substrate restriction

> “In vitro studies indicated VX-147 is a weak inducer of CYP3A4; however, in a previous clinical study (VX18-147-001; Study 001) an interaction with midazolam, a sensitive substrate of CY3A4, indicated that VX-147 has minimal inhibitory effect.”
> “Removed the study restriction for concomitant use of sensitive CYP3A substrates, based on Study VX18-147-001 data showing that VX-147 45 mg q24h does not result in clinically meaningful CYP3A inhibition or induction.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.9.2-3"></a>

### Combined oral contraceptives: ethinyl estradiol and levonorgestrel

> “The study design was an open label, 2-period, fixed-sequence crossover study in 17 healthy female adult subjects.”
> “Steady-state plasma levels of EE and LN did not decrease in the presence of daily doses of 45 mg VX-147.”
> “There were minor (~20%) increases in AUC0-24h,ss of both EE and LN.”
> “Based on these results the magnitude of these interactions are not deemed clinically significant; therefore, coadministration of VX-147 and combined oral contraceptives containing EE and LN is unlikely to result in contraceptive failure.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
